The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.

The right mix of clarity, autonomy and recognition can transform task-focused developers into truly empowered collaborators.

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

Baltimore's beloved live music tradition, Jazzy Summer Nights is well into its 25th and final season. This farewell season, ...

The Schwab U.S. Dividend Equity ETF ( SCHD 0.20%) and Pacer Global Cash Cows Dividend ETF ( GCOW -0.43%) are two notable ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...